Kamuvudine-9 / Inflammasome Therap - LARVOL DELTA

The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis. (PubMed, Sci Transl Med) - "NRTI use was also associated with a reduction in relapse rate in individuals with MS. These findings provide a rationale for further investigating K-9 for treating MS."

Journal • Preclinical • CNS Disorders • Hepatitis B • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Multiple Sclerosis • NLRP3

Evaluation of K9 in Subjects With Diabetic Macular Edema (DME) (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Michelle Abou-Jaoude | Trial completion date: Jul 2027 ➔ Feb 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Feb 2026; Low recruitment outcome

Trial completion date • Trial primary completion date • Trial termination • Diabetic Macular Edema • Ophthalmology

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) (clinicaltrials.gov) - P1 | N=4 | Terminated | Sponsor: Peter Timoney | N=13 ➔ 4 | Trial completion date: Aug 2027 ➔ Feb 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Feb 2026; Low enrollment status

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Ophthalmology • Thyroid Eye Disease

Targeting Neuroinflammation in Alzheimer's Disease: Repurposed Nucleoside Reverse Transcriptase Inhibitors and the Therapeutic Potential of Kamuvudine-9. (PubMed, Fundam Clin Pharmacol) - "In contrast to amyloid-directed interventions, NRTIs and K-9 act on converging inflammatory and genetic mechanisms that mediate both amyloid and tau pathology, making them universal modulators of disease course. Prospects for future advances in precision medicine, nanocarrier delivery and large-scale validation of interventions may reveal a new generation of accessible, disease-modifying treatments for AD."

Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • NLRP3

Kamuvudine-9 (K9) in Diabetic Macular Edema (clinicaltrials.gov) - P1/2 | N=10 | Recruiting | Sponsor: Dr. Bryan Strelow

New P1/2 trial • Diabetic Macular Edema • Ophthalmology

Inflammasome Blockade Prevents Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: Evidence from Murine Allogeneic Transplant Models (TCT-ASTCT-CIBMTR 2026) - "We investigated the involvement of the inflammasome in activating inflammatory pathways, and its inhibitor Kamuvudine-9 (K-9) in the GI aGVHD murine model... The treatment with K-9 resulted in improved epithelial barrier integrity, reduced pro- inflammatory cytokines and cells. The reduced apoptotic cell and proliferative potential suggest inflammasome inhibition and therapeutic potential of K-9 by protecting against GI injury in aGVHD pathophysiology. Subsequent investigations will focus on defining the transcriptional and metabolomic signatures that govern the therapeutic efficacy of K-9 in attenuating aGVHD pathogenesis preclinical research on Graft versus host disease"

Preclinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation • OCLN • TNFA

Therapeutic Targeting of the Inflammasome to Mitigate Murine Sclerodermatous Chronic Graft Versus Host Disease (ASH 2024) - "In this study, we evaluated the efficiency of kamuvudine-9 (K-9), a derivative of nucleoside reverse transcriptase inhibitors, as an inflammasome inhibitor (NLRP3 and NLRC4) to reduce sclerodermatous skin cGVHD...Conclusion : Our results demonstrate that specific inhibition of NLRP3 inflammasome with K-9 has a beneficial role in ameliorating cGVHD of the skin. Future work will focus on molecular transcriptional signatures and metabolomic pathways affected by this novel approach to target cGVHD of the skin to expand not only prevention and therapeutic modalities but also pathophysiologic understanding of this disease."

Preclinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dermatopathology • Fibrosis • Graft versus Host Disease • Hematological Malignancies • Immunology • Oncology • Scleroderma • Systemic Sclerosis • CASP8 • NLRP3 • TNFA

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) (clinicaltrials.gov) - P1 | N=13 | Recruiting | Sponsor: Peter Timoney | Trial completion date: May 2025 ➔ Aug 2027 | Trial primary completion date: May 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Ophthalmology • Thyroid Eye Disease

Evaluation of K9 in Subjects with Diabetic Macular Edema (DME) (clinicaltrials.gov) - P1 | N=5 | Recruiting | Sponsor: Michelle Abou-Jaoude | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Macular Edema • Ophthalmology

Evaluation of K9 in Subjects with Diabetic Macular Edema (DME) (clinicaltrials.gov) - P1 | N=5 | Not yet recruiting | Sponsor: Michelle Abou-Jaoude

New P1 trial • Diabetic Macular Edema • Ophthalmology

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: Peter Timoney | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology • Thyroid Eye Disease

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Peter Timoney

New P1 trial • Ophthalmology • Thyroid Eye Disease